Developing a novel therapeutic strategy targeting Kallikrein-4 to inhibit prostate cancer growth and metastasis
Abstract
Kallikrein-related peptidase 4 (KLK4) is a rational therapeutic target for prostate cancer (PCa) as it is up-regulated in both localised and bone metastatic tissue, and has been reported to increase PCa cell proliferation, induce epithelial-to-mesenchymal (EMT)-like changes, and could have a role in PCa homing to bone. We therefore hypothesize that blockade of KLK4 activity will inhibit PCa growth and prevent metastasis to secondary sites like bone. This project aims to develop a novel therapeutic strategy targeting KLK4 specifically in PCa. KLK4 siRNA is incorporated into a novel polymeric-based drug-delivery platform currently in development by our laboratory (Queensland University of Technology) with collaborators from the Australian Institute of Bioengineering and Nanotechnology (AIBN), University of Queensland. In this drug-delivery system, the KLK4 siRNA is conjugated to a hyperbranched polymer (HBP) backbone, which is also attached at the periphery with a short peptide that binds to prostate specific membrane antigen (PSMA; expressed on 90% of PCa) for prostate-specific delivery of the therapeutic cargo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2017
- Accession Number
- AD1052098
Entities
People
- Brian Tse
Organizations
- Queensland University of Technology